Efficacy of Angiotensin Receptor Blockers for Nocturnal Blood Pressure Reduction: a Systematic Review and Meta-analysis

Overview

Journal Ann Med

Publisher Informa Healthcare

Specialty General Medicine

Date 2024 Jun 3

PMID 38830046

Authors

Jing Liu

Wei Chen

Shihuan Shao

Yuanyuan Chen

Hongyi Wang

Yang Xi

Luyan Wang

Affiliations

Soon will be listed here.

Abstract

Background: Nocturnal blood pressure (BP) is correlated with an increased risk of cardiovascular events and is an important predictor of cardiovascular death in hypertensive patients.

Objective: Nocturnal BP control is of great importance for cardiovascular risk reduction. This systematic review and meta-analysis aimed to explore the efficacy of angiotensin receptor blockers (ARBs) for nocturnal BP reduction in patients with mild to moderate hypertension.

Methods: PICOS design structure was used to formulate the data extraction. All statistical calculations and analyses were performed with R.

Results: Seventy-seven studies with 13,314 participants were included. The overall analysis indicated that nocturnal BP drop varied considerably among different ARBs. Allisartan (13.04 [95% CI (-18.41, -7.68)] mmHg), olmesartan (11.67 [95% CI (-14.12, -9.21)] mmHg), telmisartan (11.11 [95% CI (-12.12, -10.11)] mmHg) were associated with greater reduction in nocturnal systolic BP. In the aspect of the nocturnal-diurnal BP drop ratio, only allisartan was greater than 1. While, the variation tendency of last 4-6 h ambulatory BP was basically consistent with nocturnal BP. Additionally, allisartan showed improvement effect in the proportion of patients with dipping BP pattern.

Conclusions: This study demonstrates that for patients with mild to moderate hypertension, allisartan, olmesartan and telmisartan have more advantages in nocturnal BP reduction among the ARBs, while allisartan can reduce nighttime BP more than daytime BP and improve the dipping pattern.

Citing Articles

Efficacy and Safety of Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled by Amlodipine: A Phase III, Multicenter, Double-Blind, Parallel-Group, Randomized Controlled Trial.

Chi H, Zhang X, Ma S, Pan G, Lian X, Chen Y J Clin Hypertens (Greenwich). 2025; 27(1):e14955.

PMID: 39821945 PMC: 11771783. DOI: 10.1111/jch.14955.

References

Turak O, Ozcan F, Tok D, Isleyen A, Sokmen E, Tasoglu I . Serum uric acid, inflammation, and nondipping circadian pattern in essential hypertension. J Clin Hypertens (Greenwich). 2013; 15(1):7-13. PMC: 8108262. DOI: 10.1111/jch.12026. View

White W, Weber M, Davidai G, Neutel J, Bakris G, Giles T . Ambulatory blood pressure monitoring in the primary care setting: assessment of therapy on the circadian variation of blood pressure from the MICCAT-2 Trial. Blood Press Monit. 2005; 10(3):157-63. DOI: 10.1097/00126097-200506000-00008. View

Neutel J, Kolloch R, Plouin P, Meinicke T, Schumacher H . Telmisartan vs losartan plus hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension--a randomised ABPM study. J Hum Hypertens. 2003; 17(8):569-75. DOI: 10.1038/sj.jhh.1001592. View

Madero M, Rodriguez Castellanos F, Jalal D, Villalobos-Martin M, Salazar J, Vazquez-Rangel A . A pilot study on the impact of a low fructose diet and allopurinol on clinic blood pressure among overweight and prehypertensive subjects: a randomized placebo controlled trial. J Am Soc Hypertens. 2015; 9(11):837-44. DOI: 10.1016/j.jash.2015.07.008. View

Chung O, Hinder M, Sharma A, Bonner G, Middeke M, Platon J . Comparison of the efficacy and safety of losartan (50-100 mg) with the T-type calcium channel blocker mibefradil (50-100 mg) in mild to moderate hypertension. Fundam Clin Pharmacol. 2000; 14(1):31-41. DOI: 10.1111/j.1472-8206.2000.tb00391.x. View

Huo Y, Li W, Webb R, Zhao L, Wang Q, Guo W . Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with essential hypertension: A randomized, double-blind, 8-week study. J Clin Hypertens (Greenwich). 2018; 21(1):67-76. PMC: 8030324. DOI: 10.1111/jch.13437. View

Liu J, Su X, Nie Y, Zeng Z, Chen H . Nocturnal blood pressure rather than night-to-day blood pressure ratio is related to arterial stiffening in untreated young and middle-aged adults with non-dipper hypertension. J Clin Hypertens (Greenwich). 2022; 24(8):1044-1050. PMC: 9380157. DOI: 10.1111/jch.14546. View

Lee H, Kim C, Song J, Chae S, Jeong M, Kim D . 24-Hour blood pressure response to lower dose (30 mg) fimasartan in Korean patients with mild to moderate essential hypertension. Korean J Intern Med. 2017; 32(6):1025-1036. PMC: 5668394. DOI: 10.3904/kjim.2016.094. View

Lacourciere Y, Asmar R . A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study..... Am J Hypertens. 2000; 12(12 Pt 1-2):1181-7. DOI: 10.1016/s0895-7061(99)00142-9. View

10.

Mallion J, Siche J, Lacourciere Y . ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens. 1999; 13(10):657-64. DOI: 10.1038/sj.jhh.1000925. View

11.

Xiao Y, Miao Z, Sun J, Xing W, Wei Y, Bai J . Allisartan Isoproxil Promotes Uric Acid Excretion by Interacting with Intestinal Urate Transporters in Hyperuricemic Zebrafish (Danio rerio). Bull Exp Biol Med. 2023; 175(5):638-643. DOI: 10.1007/s10517-023-05917-9. View

12.

Williams B, Lacourciere Y, Schumacher H, Gosse P, Neutel J . Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials. J Hum Hypertens. 2009; 23(9):610-9. DOI: 10.1038/jhh.2009.4. View

13.

Giles T, Alessi T, Purkayastha D, Zappe D . Comparative efficacy of aliskiren/valsartan vs valsartan in nocturnal dipper and nondipper hypertensive patients: a pooled analysis. J Clin Hypertens (Greenwich). 2012; 14(5):299-306. PMC: 8108859. DOI: 10.1111/j.1751-7176.2012.00608.x. View

14.

Hermida R, Calvo C, Ayala D, Lopez J . Decrease in urinary albumin excretion associated with the normalization of nocturnal blood pressure in hypertensive subjects. Hypertension. 2005; 46(4):960-8. DOI: 10.1161/01.HYP.0000174616.36290.fa. View

15.

Chung W, Ihm S, Jang S, Her S, Park C, Lee J . Effect of Fimasartan versus Valsartan and Olmesartan on Office and Ambulatory Blood Pressure in Korean Patients with Mild-to-Moderate Essential Hypertension: A Randomized, Double-Blind, Active Control, Three-Parallel Group, Forced Titration,.... Drug Des Devel Ther. 2020; 14:347-360. PMC: 6986172. DOI: 10.2147/DDDT.S231293. View

16.

Brunner H, Stumpe K, Januszewicz A . Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Investig. 2007; 23(7):419-30. DOI: 10.2165/00044011-200323070-00001. View

17.

Izzo Jr J, Jia Y, Zappe D . Influence of Age and Race on 24-Hour Ambulatory Blood Pressure Responses to Valsartan, Hydrochlorothiazide, and Their Combination: Implications for Clinical Practice. J Clin Hypertens (Greenwich). 2016; 19(2):143-150. PMC: 8031356. DOI: 10.1111/jch.12891. View

18.

Ribeiro A, Mion Jr D, Marin M, Majul C, Botero R, Lopez R . Antihypertensive efficacy of amlodipine and losartan after two 'missed' doses in patients with mild to moderate essential hypertension. J Int Med Res. 2007; 35(6):762-72. DOI: 10.1177/147323000703500604. View

19.

Baguet J, Nisse-Durgeat S, Mouret S, Asmar R, Mallion J . A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring. Int J Clin Pract. 2006; 60(4):391-8. DOI: 10.1111/j.1368-5031.2006.00903.x. View

20.

Cagli K, Turak O, Canpolat U, Ozcan F, Tok D, Mendi M . Association of Serum Uric Acid Level With Blood Pressure Variability in Newly Diagnosed Essential Hypertension. J Clin Hypertens (Greenwich). 2015; 17(12):929-35. PMC: 8031696. DOI: 10.1111/jch.12641. View